This podcast, Part 2 of a 3-part series on thyroid eye disease (TED), provides an in-depth discussion of treatment strategies, focusing on current medical and surgical options as well as emerging therapies. Faculty review clinical data on teprotumumab, the only FDA-approved agent for TED. Listeners will also be introduced to clinical data on treatments including glucocorticoids, orbital radiation, rituximab, and tocilizumab and learn how to select appropriate therapies across a spectrum of disease activity and duration.